{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:00:09Z","timestamp":1783702809323,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12888-016-0778-9","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T17:56:59Z","timestamp":1458323819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia"],"prefix":"10.1186","volume":"16","author":[{"given":"Yoshio","family":"Hirayasu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Shuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitaro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Funatogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiko","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"issue":"3","key":"778_CR1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","volume":"162","author":"P Milev","year":"2005","unstructured":"Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow up. Am J Psychiatry. 2005;162(3):495\u2013506.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"778_CR2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2006.00947.x","volume":"115","author":"SM Stahl","year":"2007","unstructured":"Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand. 2007;115(1):4\u201311.","journal-title":"Acta Psychiatr Scand"},{"issue":"1\u20133","key":"778_CR3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.schres.2008.11.007","volume":"108","author":"D Novick","year":"2009","unstructured":"Novick D, Haro JM, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108(1\u20133):223\u201330.","journal-title":"Schizophr Res"},{"issue":"7","key":"778_CR4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00023210-200216070-00004","volume":"16","author":"JG Csernansky","year":"2002","unstructured":"Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs. 2002;16(7):473\u201384.","journal-title":"CNS Drugs"},{"issue":"1","key":"778_CR5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/oxfordjournals.schbul.a033316","volume":"24","author":"S Doering","year":"1998","unstructured":"Doering S, M\u00fcller E, K\u00f6pcke W, Pietzcker A, Gaebel W, Linden M, M\u00fcller P, M\u00fcller-Spahn F, Tegeler J, Sch\u00fcssler G. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull. 1998;24(1):87\u201398.","journal-title":"Schizophr Bull"},{"issue":"2","key":"778_CR6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00001504-200503000-00010","volume":"18","author":"PF Buckley","year":"2005","unstructured":"Buckley PF, Shendarkar N. Treatment-refractory schizophrenia. Curr Opin Psychiatry. 2005;18(2):165\u201373.","journal-title":"Curr Opin Psychiatry"},{"issue":"8","key":"778_CR7","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1176\/ps.2006.57.8.1094","volume":"57","author":"MH Chakos","year":"2006","unstructured":"Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv. 2006;57(8):1094\u2013101.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"778_CR8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4088\/JCP.v63n0201","volume":"63","author":"SM Stahl","year":"2002","unstructured":"Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry. 2002;63(2):93\u20134.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"778_CR9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00213-005-2199-1","volume":"179","author":"MJ Millan","year":"2005","unstructured":"Millan MJ. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl). 2005;179(1):30\u201353.","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"778_CR10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","volume":"128","author":"JC Neill","year":"2010","unstructured":"Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010;128(3):419\u201332.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"778_CR11","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301\u20138.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"778_CR12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/13543784.13.5.515","volume":"13","author":"C Sur","year":"2004","unstructured":"Sur C, Kinney GG. The therapeutic potential of glycine transporter-1 inhibitors. Expert Opin Investig Drugs. 2004;13(5):515\u201321.","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"778_CR13","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archpsyc.62.11.1196","volume":"62","author":"HY Lane","year":"2005","unstructured":"Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62(11):1196\u2013204.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"778_CR14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biopsych.2007.04.038","volume":"63","author":"HY Lane","year":"2008","unstructured":"Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, Tsai GE. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63(1):9\u201312.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"778_CR15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S1461145709990939","volume":"13","author":"HY Lane","year":"2010","unstructured":"Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13(4):451\u201360.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"778_CR16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2013.02.020","volume":"74","author":"CC Huang","year":"2013","unstructured":"Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, Tun R, Huang KH, Chang YC, Lane HY, et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry. 2013;74(10):734\u201341.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"778_CR17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.biopsych.2006.04.005","volume":"60","author":"HY Lane","year":"2006","unstructured":"Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai G. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry. 2006;60(6):645\u20139.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"778_CR18","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.neuropharm.2011.11.008","volume":"62","author":"D Alberati","year":"2012","unstructured":"Alberati D, Moreau JL, Lengyel J, Hauser N, Mory R, Borroni E, Pinard E, Knoflach F, Schlotterbeck G, Hainzl D, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. 2012;62(2):1152\u201361.","journal-title":"Neuropharmacology"},{"issue":"Suppl 1","key":"778_CR19","first-page":"306","volume":"37","author":"C Hofmann","year":"2011","unstructured":"Hofmann C, Alberati D, Banken L, Boetsch C, Ereshefsky L, Jhee S, Moran S, Martin-Facklam M, Backholer Z, Boutouyrie-Dumont B. Glycine transporter type 1 (GlyT1) inhibitor RG1678: proof of mechanism of action in healthy volunteers. Schizophr Bull. 2011;37 Suppl 1:306.","journal-title":"Schizophr Bull"},{"issue":"2","key":"778_CR20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1085\/jgp.93.2.321","volume":"93","author":"PA King","year":"1989","unstructured":"King PA, Gunn RB. Na- and Cl-dependent glycine transport in human red blood cells and ghosts: a study of the binding of substrates to the outward-facing carrier. J Gen Physiol. 1989;93(2):321\u201342.","journal-title":"J Gen Physiol"},{"issue":"7","key":"778_CR21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bbamcr.2006.05.005","volume":"1763","author":"RS Ajioka","year":"2006","unstructured":"Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim Biophys Acta. 2006;1763(7):723\u201336.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"778_CR22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull"},{"issue":"12","key":"778_CR23","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","volume":"58","author":"SR Marder","year":"1997","unstructured":"Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538\u201346.","journal-title":"J Clin Psychiatry"},{"key":"778_CR24","first-page":"218","volume-title":"ECDEU assessment manual for psychopharmacology, revised","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville: US Department Health, Education, and Welfare publication; 1976. p. 218\u201322."},{"issue":"3","key":"778_CR25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter Jr WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441\u20139.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"778_CR26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2000.101004323.x","volume":"101","author":"PL Morosini","year":"2000","unstructured":"Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"778_CR27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","volume":"71","author":"D Umbricht","year":"2014","unstructured":"Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014;71(6):637\u201346.","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"778_CR28","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","volume":"24","author":"D Bugarski-Kirola","year":"2014","unstructured":"Bugarski-Kirola D, Wang A, Abi-Saab D, Bl\u00e4ttler T. A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study. Eur Neuropsychopharmacol. 2014;24(7):1024\u201336.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9831","key":"778_CR29","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063\u201371.","journal-title":"Lancet"},{"issue":"3","key":"778_CR30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000069738","volume":"72","author":"M Fava","year":"2003","unstructured":"Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115\u201327.","journal-title":"Psychother Psychosom"},{"issue":"2","key":"778_CR31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.psychres.2007.11.012","volume":"161","author":"H Nasrallah","year":"2008","unstructured":"Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008;161(2):213\u201324.","journal-title":"Psychiatry Res"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-016-0778-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T10:04:26Z","timestamp":1600337066000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-244X\/16\/66"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1186\/s12888-016-0778-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]},"article-number":"66"}}